First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Study Name
First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
ClinicalTrials.gov Identifier (if applicable)
NCT04526106
Clinical Trial Category (check all that apply)
  • First Line Therapy
  • Beyond First Line Therapy
  • Targeted Therapy
Study Center
Institution Name
Please see clinicaltrials.gov
Country
United States
Study Contacts
Principal Investigator
Please see clinicaltrials.gov
P.I. Phone
(339) 230-7475
P.I. Email
ClinicalTrials@relaytx.com
Study Coordinator
Please see clinicaltrials.gov
Study Coordinator Phone
(339) 230-7475
Study Coordinator Email
ClinicalTrials@relaytx.com
OVERVIEW – in layman’s terms (150 words max)
This clinical trial is studying the safety and effectiveness of an investigational drug for patients with Cholangiocarcinoma and other solid tumors that meet eligibility requirements. This investigational drug is a highly selective Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitor. Please refer to Clinicaltrials.gov for more information.
Enrollment
Ongoing
Study Start Date
09/01/2020
Estimated Completion Date
10/01/2024